Impact of early anti-TNF use on clinical outcomes in Crohn’s disease: a nationwide population-based study
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: The optimal timing for initiation of anti-tumor necrosis factor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about the clinical outcomes of early versus late administration of anti-TNF agents, especially in Asian CD patients. We aimed to evaluate the impact of early anti-TNF therapy on clinical outcomes in Korean CD patients. Methods: Using the Korean National Health Insurance Claims database, we collected data on patients diagnosed with CD who received anti-TNF therapy for more than 6 months between 2010 and 2016. Early initiation of anti-TNF therapy was defined as those starting infliximab or adalimumab therapy within 1 year of diagnosis. The following outcomes were assessed using a Cox proportional hazard model: abdominal surgery, CD-related emergency room (ER) visit, CD-related hospitalization, and new corticosteroid use. Results: Among 1,207 patients, 609 were early initiators of anti-TNF. Late anti-TNF initiation (> 1 year after diagnosis) was associated with increased risk of surgery (adjusted hazard ratio [aHR], 1.64; 95% confidence interval [CI], 1.05 to 2.55) and tended to be associated with increased risk of ER visit (aHR, 1.38; 95% CI, 0.99 to 1.94). However, there were no significant differences in the risk of hospitalization and corticosteroid use between early and late initiators. Conclusions: Early anti-TNF therapy among Korean CD patients within 1 year of diagnosis was associated with better clinical outcomes than late therapy, such as lower surgery and ER visit rates. Our results suggest that aggressive medical intervention in the early stages of CD may potentially change the course of this disease.
Abstract
Background/Aims: The optimal timing for initiation of anti-tumor necrosis factor (TNF) therapy in Crohn’s disease (CD) is still debated. Little is known about the clinical outcomes of early versus late administration of anti-TNF agents, especially in Asian CD patients. We aimed to evaluate the impact of early anti-TNF therapy on clinical outcomes in Korean CD patients. Methods: Using the Korean National Health Insurance Claims database, we collected data on patients diagnosed with CD who received anti-TNF therapy for more than 6 months between 2010 and 2016. Early initiation of anti-TNF therapy was defined as those starting infliximab or adalimumab therapy within 1 year of diagnosis. The following outcomes were assessed using a Cox proportional hazard model: abdominal surgery, CD-related emergency room (ER) visit, CD-related hospitalization, and new corticosteroid use. Results: Among 1,207 patients, 609 were early initiators of anti-TNF. Late anti-TNF initiation (> 1 year after diagnosis) was associated with increased risk of surgery (adjusted hazard ratio [aHR], 1.64; 95% confidence interval [CI], 1.05 to 2.55) and tended to be associated with increased risk of ER visit (aHR, 1.38; 95% CI, 0.99 to 1.94). However, there were no significant differences in the risk of hospitalization and corticosteroid use between early and late initiators. Conclusions: Early anti-TNF therapy among Korean CD patients within 1 year of diagnosis was associated with better clinical outcomes than late therapy, such as lower surgery and ER visit rates. Our results suggest that aggressive medical intervention in the early stages of CD may potentially change the course of this disease.
참고문헌 (22)
- 이승훈, "Immunological pathogenesis of inflammatory bowel disease", Intestinal research, 16(1), pp.26~42 (2018), 대한장연구학회
- Choon Jin Ooi, "Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia", Intestinal research, 17(3), pp.285~310 (2019), 대한장연구학회[DOI]
- Jong Pil Im, "Changing treatment paradigms for the management of inflammatory bowel disease", The Korean Journal of Internal Medicine, 33(1), pp.28~35 (2018), 대한내과학회[DOI]
- Lichtenstein GR, "Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease", Gastroenterology, 128, pp.862~869 (2005)
- Feagan BG, "Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease : results from the CHARM study", Gastroenterology, 135, pp.1493~1499 (2008)
- Rubin DT, "Response to biologic therapy in Crohn’s disease is improved with early treatment : an analysis of health claims data", Inflamm Bowel Dis, 18, pp.2225~2231 (2012)
- Khanna R, "Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial", Lancet, 386, pp.1825~1834 (2015)
- Ma C, "Anti-TNF therapy within 2 years of Crohn’s disease diagnosis improves patient outcomes : a retrospective cohort study", Inflamm Bowel Dis, 22, pp.870~879 (2016)
- Safroneeva E, "Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn’s disease", Aliment Pharmacol Ther, 42, pp.977~989 (2015)
- Frei R, "Early initiation of anti-TNF is associated with favourable long-term outcome in Crohn’s disease : 10-year-follow-up data from the Swiss IBD cohort study", J Crohns Colitis, 13, pp.1292~1301 (2019)
- Oh EH, "Early anti-TNF", immunomodulator therapy is associated with better long-term clinical outcomes in Asian patients with Crohn’s disease with poor prognostic factors, 2017, pp.12, e0177479~
- Jung YS, "Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014 : a nationwide population-based study", Dig Dis Sci, 62, pp.2102~2112 (2017)
- Jung YS, "Cancer risk in the early stages of inflammatory bowel disease in Korean patients : a nationwide population-based study", J Crohns Colitis, 11, pp.954~962 (2017)
- Han M, "Regional variations in the use of biologics and immunomodulators among Korean patients with inflammatory bowel diseases", J Gastroenterol Hepatol, 34, pp.1166~1174 (2019)
- David G, "Variations in care : a retrospective database analysis of healthcare utilization patterns for patients with inflammatory bowel disease", J Med Econ, 18, pp.137~144 (2015)
- Gonzalez-Lama Y, "Timing of thiopurine or anti-TNF initiation is associated with the risk of major abdominal surgery in Crohn’s disease : a retrospective cohort study", J Crohns Colitis, 10, pp.55~60 (2016)
- Nuij V, "Benefit of earlier anti-TNF treatment on IBD disease complications", J Crohns Colitis, 9, pp.997~1003 (2015)
- Park KT, "Health insurance paid costs and drivers of costs for patients with Crohn’s disease in the United States", Am J Gastroenterol, 111, pp.15~23 (2016)
- van der Valk ME, "Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFαtherapy : results from the COIN study", Gut, 63, pp.72~79 (2014)
- Kim JW, "Long-term evolution of direct healthcare costs for inflammatory bowel diseases : a population-based study(2006-2015)", Scand J Gastroenterol, 54, pp.419~426 (2019)
- Beilman CL, "Early initiation of tumor necrosis factor antagonist-based therapy for patients with Crohn’s disease reduces costs compared with late initiation", Clin Gastroenterol Hepatol, 17, pp.1515~1524 (2019)
- Juillerat P, "Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond : a multicenter international cohort", Inflamm Bowel Dis, 21, pp.60~70 (2015)